<DOC>
	<DOC>NCT00496054</DOC>
	<brief_summary>To observe the safety, tolerability and immunogenicity of the administration of 3 doses of rotateq in healthy Indian infants between 6 weeks through exactly 12 weeks of age at entry.</brief_summary>
	<brief_title>Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 6 weeks through exactly 12 weeks Healthy infants Clinical evidence of active gastrointestinal illness Fever, with a rectal temperature of greater than and equal to thirty eight degree celsius at the time of immunization History of congenital abdominal disorders, intussusception, or abdominal surgery History of known prior rotavirus disease Known or suspected impairment of immunological function Prior administration of any rotavirus vaccine Known hypersensitivity to any component of the rotavirus vaccine, e.g. trypsin</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>